Dzvanya apa kana iri pepanhau rako!

Childhood Asthma: Kurapwa Kutsva Kunoderedza Zvinonyanya Kurwiswa NeAsma

rakanyorwa mupepeti

Regeneron Pharmaceuticals, Inc. uye Sanofi nhasi vakazivisa kuti New England Journal of Medicine yakabudisa migumisiro yakanaka kubva kune yakakosha Dupixent® (dupilumab) yekiriniki yekuedza muvana vane makore 6 kusvika kumakore gumi nerimwe vane asthma isingadzorwi pakati-kusvika-yakaoma. Idzi dhata dzakagadzira hwaro hwekubvumidzwa kweFDA kweDupixent muna Gumiguru 11, 20 sekuwedzera-pakuchengetedza kurapwa kwevarwere vane makore matanhatu kusvika gumi nerimwe vane asthma yepakati-kusvika-yakanyanya inoratidzwa ne eosinophilic phenotype kana nemuromo corticosteroid-inotsamira asima.

Print Friendly, PDF & Email

Izvi zvakabudiswa zvakaratidza Dupixent, kana yakawedzerwa kuhutano hwehutano, yakaderedza zvakanyanya kurwiswa kweasma uye, mukati memavhiki maviri, yakakurumidza kuvandudza kushanda kwemapapu muhuwandu hwevanhu vane eosinophilic phenotype, sezvinoratidzwa nepamusoro yeeosinophils yeropa, imwe rudzi rweropa chena, uye/kana ine yakakwira fractional exhaled nitric oxide (FeNO), mugwagwa wemhepo biomarker yekuzvimba inoita basa guru muasthma.

"Kudhindwa kweizvi Phase 3 mhedzisiro yeDupixent muNew England Journal of Medicine inosimbisa kukosha kwavo uye inogona kuve yakakosha yekiriniki yevana vadiki vane isingadzorerwe pakati-kusvika-yakanyanya asima," akadaro Leonard B. Bacharier, MD, Purofesa wePediatrics uye Director. weCentre for Pediatric Asthma Research, Monroe Carell Jr. Children's Hospital paVanderbilt University Medical Center muNashville, Tennessee, uye mukuru anoongorora nyaya yacho. "Idzi data dzinowedzerawo manzwisisiro edu ekugadzirisa kuzvimba kwerudzi rwechipiri, chirongwa chebhayoloji chinokonzera zviitiko zvakawanda zveasima muhuduku, zvinogona kuvandudza zviratidzo nemhedzisiro kuvana vanorwara nechirwere ichi chisingaperi."

Asthma ndechimwe chezvirwere zvinowanzoitika muvana. Vanosvika zviuru makumi manomwe nezvishanu vana vane makore matanhatu kusvika gumi nerimwe vanorarama nehurwere husingadzoreki huri pakati nepakati-kusvika-hwakanyanya muUS, uye zvimwe zvakawanda pasi rose. Pasinei nekurapwa neazvino chiyero-yekutarisira inhaled corticosteroids uye bronchodilators, vana ava vanogona kuramba vachiona zviratidzo zvakakomba senge kukosora, kufema uye kunetseka kufema. Ivo zvakare vangangoda akawanda makosi e systemic corticosteroids anogona kutakura akakosha ekuchengetedza njodzi.

Migumisiro yekuchengetedzwa kubva mukuedzwa yaiwanzoenderana neyakazivikanwa kuchengetedzwa kweDupixent muvarwere vane makore gumi nemaviri uye kupfuura vane isingadzoreki pakati-kusvika-yakaoma asthma, pamwe nekuwedzera kwezvirwere zvehelminth zvakashumwa mu12% yevarwere veDupixent uye 2.2% yevarwere ve placebo. Izvo zviyero zvezviitiko zvakashata zvaive 0.7% yeDupixent uye 83% ye placebo. Zviitiko zvakaipisisa zvaiwanzoonekwa neDupixent zvichienzaniswa ne placebo zvaive jekiseni site reactions (80% Dupixent, 18% placebo), utachiona hwepamusoro hwekufema hutachiwana (13% Dupixent, 12% placebo) uye eosinophilia (10% Dupixent, 6% placebo).

Dupixent, iyo yakagadzirwa uchishandisa Regeneron's proprietary VelocImmune® tekinoroji, ndeye munhu akazara monoclonal antibody inodzivirira kusaina kweiyo interleukin-4 (IL-4) uye interleukin-13 (IL-13) nzira uye haisi immunosuppressant. IL-4 uye IL-13 ndiwo akakosha uye epakati madhiraivha erudzi rwechipiri kuzvimba kunoita basa rakakura muatopic dermatitis, asthma uye chisingaperi rhinosinusitis ine nasal polyposis (CRSwNP).

Mhedzisiro yeiyi Phase 3 muyedzo yakaverengerwa muEuropean regulatory faira, uye sarudzo kubva kuEuropean Medicines Agency muvana vane isingadzoreki yakakomba asthma inotarisirwa muQ1 2022.

Print Friendly, PDF & Email

Nezvomunyori

mupepeti

Mupepeti mukuru ndiLinda Hohnholz.

Leave a Comment